C4 Therapeutics, Inc. (CCCC)

6,74 +0,31 (+4,82%) Alla chiusura: 04:00PM EDT

C4 Therapeutics, Inc.

490 Arsenal Way
Suite120
Watertown, MA 02472
United States
617 231 0700
https://www.c4therapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 145

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director	986,08k	N/D	1971
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board	45k	N/D	1951
Dr. Stewart Fisher Ph.D.	Chief Scientific Officer	674,57k	N/D	1967
Dr. Leonard M. J. Reyno M.D.	Chief Medical Officer	1,04M	N/D	1962
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Ms. Kendra Adams	CFO & Treasurer	N/D	N/D	N/D
Mr. Mark Mossler	Chief Accounting Officer	N/D	N/D	1973
Ms. Jolie M. Siegel J.D.	Chief Legal Officer & Corporate Secretary	610,4k	1,06M	1977
Ms. Kelly A. Schick	Chief People Officer	N/D	N/D	1980
Dr. Isabel Chiu Ph.D.	Senior Vice President of Strategic Alliances & Business Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di C4 Therapeutics, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.